Middle East and Africa Ataxia Market, By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2029.
Middle East and Africa Ataxia Market Analysis and Insights
The growing prevalence of ataxia disease has enhanced the market's demand. The rising healthcare expenditure for better health services also contributes to the market's growth. During this crucial period, the major market players are highly focused on product launches and product approvals. In addition, the government and regulatory bodies are supporting market players by product approval due to surging emergence.
The Middle East and Africa ataxia market is growing in the forecast year due to the rise in market players and the availability of advanced products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market. The increasing research in the field of ataxia therapeutics and the rise in consumption of alcohol and drugs usage are expected to boost the market growth further. However, the difficulty in diagnosing the disease and the lack of genetic testing facilities in some developing countries might hamper the growth of the Middle East and Africa ataxia market in the forecast period.
The rising healthcare expenditure and strategic initiatives by market players may give the market opportunities to enhance the treatment. However, some stringent rules and regulations associated with the approval of drugs and products and product recall from various companies are expected to challenge the market growth.
Middle East and Africa ataxia market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.6% in the forecast period of 2022 to 2029 and is expected to reach USD 518.38 thousand by 2029 from USD 377.38 thousand in 2021.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020
|
|
Quantitative Units
|
Revenue in USD thousand, Pricing in USD
|
|
Segments Covered
|
By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, the Rest of the Middle East and Africa
|
|
Market Players Covered
|
Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others
|
Market Definition
Ataxia is a term for a group of disorders that affect coordination, balance, and speech. Anybody part can be affected, but people with ataxia often have difficulties with balance, walking, speaking, swallowing, and tasks requiring a high degree of control, such as writing, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.
Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected.
Middle East and Africa Ataxia Market Dynamics
Drivers
- Rapid research in the field of ataxia therapeutics
There is an enormous range of risk factors being reported for ataxia. Hence, to reduce the risk factors and symptoms associated with it, various research is going on in ataxia treatments. Some government funding has also been initiated to treat various types of ataxia in the market. Various rapid research in the field of ataxia therapeutics may help drive the market over the forecasted period and anticipate the major growth in the research and development for the same.
- Rise in alcohol and drug usage
Rising alcohol and drug usage can lead to vitamin B-12, vitamin E, and thiamine deficiency. The lack of these nutrients in the body is considered to be a major cause of ataxia. A shortage of vitamin E in the body can lead to neurological problems, such as difficulty coordinating movements (ataxia) and speech (dysarthria), loss of reflexes in the legs (lower limb areflexia), and a loss of sensation in the extremities (peripheral neuropathy) this then leads to the various types ataxia. The rising number of people and youth consuming excessive alcohol and drugs also increases the chance of being affected by various types of ataxia. This is expected to act as a driver for the growth of the Middle East and Africa ataxia market.
Opportunities
- Rising healthcare expenditure
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for ataxia as the disorder has been highly prevalent in recent years.
Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the ataxia market in the forecast period of 2022-2029.
Restraints/Challenges
However, the difficulty in diagnosing the disease and lack of genetic testing facilities in some developing countries will impede the growth rate of the Middle East and Africa ataxia market. Additionally, stringent rules and regulations will further challenge the forecast period's market.
This Middle East and Africa ataxia market report provide details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa ataxia market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Middle East and Africa Ataxia Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence, various treatment drugs have widely increased in the world's population. Thus, the pandemic has positively affected this market.
Recent Development
- In November 2021, Sanofi announced that the company had completed its acquisition with Kadmon. This has helped the company expand its product portfolio and increase its revenue through various generic medicine products
Middle East and Africa Market Scope
The Middle East and Africa ataxia market is segmented into type, product, dosage form, route of administration, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Spinocerebellar Ataxias
- Ataxia-Telangiectasia
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA))
On the basis of type, the Middle East and Africa ataxia market is segmented into spinocerebellar ataxias, ataxia-telangiectasia, episodic ataxia, and others (multiple system atrophy (MSA)).
Product
- Diagnosis
- Treatment
On the basis of product, the Middle East and Africa ataxia market is segmented into treatment and diagnosis.
Dosage Form
- Solid
- Liquids
- Others
On the basis of dosage form, the Middle East and Africa ataxia market is segmented into solid, liquids, and others.
.Route Of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the Middle East and Africa ataxia market is segmented into oral, parenteral, and others.
Patient Type
- Adult
- Child
- Geriatric
On the basis of patient type, the Middle East and Africa ataxia market is segmented into adult, child, and geriatric.
End User
- Hospital
- Clinics
- Home Healthcare
- Others
On the basis of end users, the Middle East and Africa ataxia market is segmented into hospital, clinics, home healthcare, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the Middle East and Africa ataxia market is segmented into direct tender, retail sales, and others.
Middle East and Africa Ataxia Market Regional Analysis/Insights
The Middle East and Africa ataxia market is analyzed and market size insights and trends are provided by country, type, product, dosage form, route of administration, patient type, end user, and distribution channel.
Some of the countries covered in this region are South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, the rest of the Middle East and Africa. South Africa is expected to dominate the Middle East and Africa ataxia market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of ataxia in the region, and rapid research development is boosting the market.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and African brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Ataxia Market Share Analysis
Middle East and Africa ataxia market competitive landscape provide details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa ataxia market.
Some of the major players operating in the Middle East and Africa ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Cipla Inc., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-